The team redefining women’s health through science designed for her
At J3, we’re rethinking how therapies are developed for women — working with her biology, not against it.
Our patented LIV-Ring platform delivers continuous, controlled release of active and functional ingredients, offering women long-lasting comfort, consistency, and confidence. Our technology is built to align with her body.
Our purpose
To develop and deliver science-backed solutions that improve women’s health by working with her biology, not against it.
Our core values
Scientific integrity: we are grounded in data, purpose driven.
Accountability: we take ownership of outcomes and results.
Focus: we develop products exclusively for women’s health.
Partnership: we collaborate to accelerate meaningful change.
Our culture
At J3, collaboration drives discovery, and diversity of experience fuels innovation. We measure success not only by milestones achieved, but by the lives we improve.
Our culture emphasizes curiosity, accountability, and a shared commitment to excellence. We empower teams to think creatively, move with purpose, and solve real problems for real women.
Above all, we believe the best innovations come from teams who care deeply about the people they serve—and who are united by the ambition to elevate women's health through meaningful, innovative solutions.
Our story
J3 was founded on a simple idea:
Women deserve therapies designed to with their biology, not against it.
Built on deep expertise in biomedical engineering, materials science, and women’s health, our team brings decades of experience in drug delivery, clinical innovation, and translational science. From the beginning, we set out to close the gaps women have faced for far too long—creating solutions that are grounded in biology, guided by evidence, and engineered for real-world impact.
The team redefining women’s health
It takes a visionary, determined team to transform how women experience care—one that brings scientific rigor, engineering excellence, and deep industry experience together with an unwavering commitment to improving women’s lives.
Executive leadership
John Fair
President & CEO
20+ years of leadership across drug, device, and Dx development. Deep women’s health product and brand commercialization experience. Transformational transactions and partnerships (Bayer, Organon, Pfizer), and over $1B in value creation through financing, licensing, and M&A.
Qun Xu, CFA
Head of Finance
Seasoned finance leader with 20 years’ experience in strategic finance, fundraising, and investor relations across high-growth med-tech and life-sciences ventures.
R. Tyler McCabe, PhD
CSO & Co-Founder
35+ years advancing device, pharma, and diagnostic innovation; veteran R&D leader and inventor with over 100 scientific publications and multiple issued patents.
Stephanie Singer, MD, FACOG
Medical Director
Board-certified OB-GYN and women’s health innovator specializing in pelvic pain, sexual wellness, and hormone therapy, guiding clinical strategy for VR101 and beyond.
Scientific & strategic advisors
Sheryl Kingsberg, PhD
Board Director & Special Medical Advisor
Chief, Division of Behavioral Medicine, Department of OB/GYN, University Hospitals Cleveland Medical Center
Lindsay Burt, MD
Special Clinical Advisor
Associate Professor, Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah
Ray Jordan
Corporate Affairs & Investor Relations Advisor
Principal, Putnam Insights; former senior communications leader at Johnson & Johnson, Amgen, and Pfizer
At a glance
4 U.S. and 11 international patents
FDA-cleared technology (VR101)
Leadership across device, pharma, and women’s health